2024
BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review
Feng S, Xiong Y, Liu W, Liu H, Sui W, Zheng P, Sun M, Hu K, Zhang Y. BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review. Critical Reviews In Oncology/Hematology 2024, 205: 104551. PMID: 39510436, DOI: 10.1016/j.critrevonc.2024.104551.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaPlasmablastic lymphomaCAR-TLymphocytic leukemiaTransformation of chronic lymphocytic leukemiaCAR-T cell treatmentBruton tyrosine kinase inhibitorPatient's chronic lymphocytic leukemiaRight supraclavicular massNovel targeted agentsTyrosine kinase inhibitorsRichter transformationSupraclavicular massBrentuximab vedotinTargeted therapyTargeted agentsRare caseBone marrowCase reportTherapy choiceKinase inhibitorsInnovative therapiesCell treatmentTherapyBCMAChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Wierda W, Brown J, Abramson J, Awan F, Bilgrami S, Bociek G, Brander D, Cortese M, Cripe L, Davis R, Eradat H, Fakhri B, Fletcher C, Gaballa S, Hamid M, Hill B, Kaesberg P, Kahl B, Kamdar M, Kipps T, Ma S, Mosse C, Nakhoda S, Parikh S, Schorr A, Schuster S, Seshadri M, Siddiqi T, Stephens D, Thompson M, Ujjani C, Valdez R, Wagner-Johnston N, Woyach J, Sundar H, Dwyer M. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 175-204. PMID: 38626800, DOI: 10.6004/jnccn.2024.0018.Peer-Reviewed Original ResearchConceptsSmall lymphocytic lymphomaChronic lymphocytic leukemiaPredictor of improved survivalUndetectable minimal residual diseaseImmunoglobulin heavy chain variable region mutational statusMinimal residual diseaseManagement of patientsSelection of treatmentRelapsed/refractory CLL/SLLLymphocytic lymphomaResidual diseaseCombination regimensTP53 mutationsMutation statusPerformance statusLymphocytic leukemiaNCCN guidelinesPatient agePrognostic implicationsToxicity profileDisease stageComorbid conditionsPatientsCLL/SLLCytogenetic variabilityReal‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia
Huntington S, de Nigris E, Puckett J, Kamal‐Bahl S, Farooqui M, Ryland K, Sarpong E, Leng S, Yang X, Doshi J. Real‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia. Cancer Medicine 2024, 13: e6953. PMID: 38348963, PMCID: PMC10832339, DOI: 10.1002/cam4.6953.Peer-Reviewed Original ResearchMeSH KeywordsAdenineAgedHumansLeukemia, Lymphocytic, Chronic, B-CellMedicarePiperidinesProtein Kinase InhibitorsUnited StatesConceptsChronic lymphocytic leukemiaRate of adverse eventsIncidence rate of adverse eventsAdverse eventsPatient-monthsLymphocytic leukemiaIncidence ratePatients treated with ibrutinibTreatment of chronic lymphocytic leukemiaStandard-of-care therapyNon-discontinuationInitiation of ibrutinibBTK inhibitor ibrutinibAdverse event ratesPotential side effectsInhibitor ibrutinibMedicare beneficiariesReal-world analysisAtrial fibrillationFollow-upIbrutinibSide effectsReal-world outcomesEvent ratesLeukemia
2023
Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia
Huntington S, de Nigris E, Puckett J, Kamal-Bahl S, Farooqui M, Ryland K, Sarpong E, Leng S, Yang X, Doshi J. Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia. Leukemia & Lymphoma 2023, 64: 2286-2295. PMID: 37870435, DOI: 10.1080/10428194.2023.2256911.Peer-Reviewed Original ResearchMeSH KeywordsAdenineAgedHumansLeukemia, Lymphocytic, Chronic, B-CellMedicarePiperidinesUnited StatesConceptsChronic lymphocytic leukemiaIbrutinib discontinuationLymphocytic leukemiaHalf of patientsMonths of initiationElderly Medicare beneficiariesLarge unmet needPart D low-income subsidyLow-income subsidyCardiovascular comorbiditiesElderly patientsReal-world practiceIbrutinib treatmentLymphocytic lymphomaAdvanced ageClinical trialsMedical CenterMedicare claimsDiscontinuationHigh riskMedicare beneficiariesUnmet needPatientsLeukemiaTwo-thirdsNegative feedback regulation of MAPK signaling is an important driver of chronic lymphocytic leukemia progression
Ecker V, Brandmeier L, Stumpf M, Giansanti P, Moreira A, Pfeuffer L, Fens M, Lu J, Kuster B, Engleitner T, Heidegger S, Rad R, Ringshausen I, Zenz T, Wendtner C, Müschen M, Jellusova J, Ruland J, Buchner M. Negative feedback regulation of MAPK signaling is an important driver of chronic lymphocytic leukemia progression. Cell Reports 2023, 42: 113017. PMID: 37792532, DOI: 10.1016/j.celrep.2023.113017.Peer-Reviewed Original ResearchConceptsMitogen-activated protein kinaseChronic lymphocytic leukemiaCLL cellsMitochondrial reactive oxygen speciesChronic lymphocytic leukemia progressionApoptotic cell deathPoor clinical prognosisCLL cell survivalSmall molecule inhibitorsNegative feedback regulationProtein kinaseReactive oxygen speciesMAPK signalingMAPK activityPromising treatment conceptClinical prognosisClinical challengeLymphocytic leukemiaCell survivalAcute activationCell deathDNA damageDUSP6Treatment conceptFeedback regulationReal-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia
Huntington S, Manzoor B, Puckett J, Kamal-Bahl S, Alhasani H, Ravelo A, Jawaid D, Doshi J. Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 2023, 64: 2316-2323. PMID: 37732602, DOI: 10.1080/10428194.2023.2255326.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicHumansLeukemia, Lymphocytic, Chronic, B-CellLymphoma, B-CellMedicareRecurrenceUnited StatesConceptsChronic lymphocytic leukemiaReal-world adherenceRefractory chronic lymphocytic leukemiaTyrosine kinase inhibitorsLymphocytic leukemiaB-cell lymphoma-2 inhibitorBruton tyrosine kinase inhibitorsNovel oral agentsClinical trial dataOral agentsClinical characteristicsElderly patientsTreatment landscapeTreatment initiationReal-world findingsHigh adherenceMedicare beneficiariesLower discontinuationTrial dataDiscontinuationPatientsOlder adultsKinase inhibitorsAdherenceLeukemiaThe COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021
Goyal G, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Neparidze N, Seymour E. The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Network Open 2023, 6: e2316642. PMID: 37273206, PMCID: PMC10242428, DOI: 10.1001/jamanetworkopen.2023.16642.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCohort StudiesCOVID-19FemaleHematologic NeoplasmsHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedOutpatientsPandemicsRetrospective StudiesConceptsEarly pandemic monthsOral therapyOutpatient infusionsChronic lymphocytic leukemiaHematologic neoplasmsVisit ratesTelemedicine useCohort studyPandemic monthsLymphocytic leukemiaRetrospective observational cohort studyData cutoff datePerson medical careSubsequent cancer outcomesHalf of patientsObservational cohort studyMantle cell lymphomaCOVID-19COVID-19 pandemicNon-Hispanic whitesMedian ageActive treatmentCancer outcomesMultiple myelomaActive patientsTranscriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
Al-Sawaf O, Zhang C, Jin H, Robrecht S, Choi Y, Balasubramanian S, Kotak A, Chang Y, Fink A, Tausch E, Schneider C, Ritgen M, Kreuzer K, Chyla B, Paulson J, Pallasch C, Frenzel L, Peifer M, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nature Communications 2023, 14: 2147. PMID: 37072421, PMCID: PMC10113251, DOI: 10.1038/s41467-023-37648-w.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicChlorambucilHumansLeukemia, Lymphocytic, Chronic, B-CellTranscriptomeConceptsProgression-free survivalChronic lymphocytic leukemiaUntreated chronic lymphocytic leukemiaLymphocytic leukemiaAssociated with longer progression-free survivalParallel-group phase 3 studyProgression-free survival ratesTreatment of chronic lymphocytic leukemiaLonger progression-free survivalDepth of remissionMedian Follow-UpPhase 3 studyAssociated with increased expressionLong-term efficacyLong-term outcomesExploratory post hoc analysisPost Hoc AnalysisMRD statusBCL2 inhibitionOverall survivalPrimary endpointSecondary endpointsInflammatory response pathwaysVenetoclax-obinutuzumabFollow-upDTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study
Huntington S, Schuster S, Ding W, Koehler A, Brander D, Rosenthal A, Leis J, Tun H, Moustafa M, Iqbal M, He W, Kearney A, McKinlay T, Gui M, Mato A. DTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study. American Journal Of Hematology 2023, 98: 739-749. PMID: 36810799, DOI: 10.1002/ajh.26888.Peer-Reviewed Original ResearchConceptsBruton tyrosine kinase inhibitorsTyrosine kinase inhibitorsRefractory lymphomaTriplet combinationsKinase inhibitorsOral combination therapyPhase 2 doseOpen-label studyDose-escalation studyAccelerated titration designB-cell NHLNovel Bruton's tyrosine kinase inhibitorEligible patientsEverolimus 5Refractory CLLEscalation studyTriplet therapyMedian ageCombination therapyHodgkin's lymphomaIMiD therapyImmunomodulatory agentsClinical activityDoublet combinationsPreclinical studiesChronic Lymphocytic Leukemia Presenting as Bilateral Periorbital Edema Treated With Low-dose Radiation Therapy
Spadaro J, Chow R, Sinard J, Watsky K, Habib L. Chronic Lymphocytic Leukemia Presenting as Bilateral Periorbital Edema Treated With Low-dose Radiation Therapy. Ophthalmic Plastic And Reconstructive Surgery 2023, 39: e78-e81. PMID: 36852835, DOI: 10.1097/iop.0000000000002338.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaLow-dose radiation therapyPeriorbital edemaRadiation therapyChronic Lymphocytic Leukemia PresentingBilateral periorbital edemaLeukemia cutisOcular involvementOcular manifestationsPrompt diagnosisBlood dyscrasiasCase reportNeoplastic lymphocytesLymphocytic leukemiaTissue infiltrationTherapeutic interventionsEdemaPatientsTherapyLeukemiaInfiltrationEcchymosisPresentingDyscrasiasLymphocytes
2022
CD74 as a regulator of transcription in normal B cells
David K, Friedlander G, Pellegrino B, Radomir L, Lewinsky H, Leng L, Bucala R, Becker-Herman S, Shachar I. CD74 as a regulator of transcription in normal B cells. Cell Reports 2022, 41: 111572. PMID: 36323260, DOI: 10.1016/j.celrep.2022.111572.Peer-Reviewed Original ResearchMeSH KeywordsB-LymphocytesHistocompatibility Antigens Class IIHumansLeukemia, Lymphocytic, Chronic, B-CellProtein BindingSignal TransductionTranscription FactorsTranscription, GeneticConceptsMacrophage migration inhibitory factorNormal B cellsB cellsCytokine macrophage migration inhibitory factorRegulators of transcriptionChronic lymphocytic leukemia cellsMigration inhibitory factorNovel therapeutic pathwaysInhibition of transcriptionLymphocytic leukemia cellsTumor suppressor geneTranscriptional regulatorsTranscription factorsTherapeutic pathwaysCLL cellsFuture treatmentIntracellular domainOncogenic transformationMalignant cellsInhibitory factorRegulatory functionsPromoter areaLeukemia cellsTranscriptionGenesSYK and ZAP70 kinases in autoimmunity and lymphoid malignancies
Leveille E, Chan LN, Mirza AS, Kume K, Müschen M. SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies. Cellular Signalling 2022, 94: 110331. PMID: 35398488, DOI: 10.1016/j.cellsig.2022.110331.Peer-Reviewed Original ResearchMeSH KeywordsAdultAutoimmune DiseasesAutoimmunityHumansLeukemia, Lymphocytic, Chronic, B-CellPhosphatidylinositol 3-KinasesReceptors, Antigen, B-CellSyk KinaseZAP-70 Protein-Tyrosine KinaseConceptsChronic lymphocytic leukemiaB-cell malignanciesT cell receptorB cell receptorB-cell chronic lymphocytic leukemiaPathological B-cellsPoor clinical outcomeAcute lymphoblastic leukemiaExpression of SykT lymphocyte developmentClinical outcomesAggressive diseaseActivation of NFATAutoimmune diseasesLymphoblastic leukemiaT lymphocytesLymphocytic leukemiaCell lymphomaLymphoid malignanciesB cellsPI3K-pathwayOncogenic driversMalignancyNegative selectionPremalignant cellsUnexpectedly low hemoglobin A1c in a patient with chronic lymphocytic leukemia
Jacobs JW, Gisriel SD, Iyer K, Hauser RG, El-Khoury JM. Unexpectedly low hemoglobin A1c in a patient with chronic lymphocytic leukemia. Clinica Chimica Acta 2022, 531: 91-93. PMID: 35351433, DOI: 10.1016/j.cca.2022.03.012.Peer-Reviewed Original ResearchMeSH KeywordsBlood GlucoseDiabetes Mellitus, Type 2Glycated HemoglobinHumansLeukemia, Lymphocytic, Chronic, B-CellConceptsChronic lymphocytic leukemiaNeoplastic lymphocytesLymphocytic leukemiaDiabetes mellitus type 2Red blood cell survivalMellitus type 2Blood cell survivalGlycated hemoglobin assaysCertain medicationsLower hemoglobinHemolytic anemiaType 2PatientsHemoglobin assayPrecise mechanismMarked numberLymphocytesLeukemiaCell survivalFurther investigationHemoglobin variantsAssaysMedicationsAnemiaEnzymatic assay
2021
Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib
Holowka T, Cheung H, Malinis M, Gan G, Deng Y, Perreault S, Isufi I, Azar MM. Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib. Journal Of Infection And Chemotherapy 2021, 27: 1700-1705. PMID: 34389223, DOI: 10.1016/j.jiac.2021.08.005.Peer-Reviewed Original ResearchMeSH KeywordsAdenineAgedHumansIncidenceInvasive Fungal InfectionsLeukemia, Lymphocytic, Chronic, B-CellPiperidinesRisk FactorsConceptsInvasive fungal infectionsSerious infectionsRisk factorsHematologic malignanciesAdvanced ageMultivariate analysis risk factorsSmall molecule tyrosine kinase inhibitorsSingle tertiary care centerFungal infectionsConcurrent useCytotoxic agentsMolecule tyrosine kinase inhibitorsAnalysis risk factorsTertiary care centerTyrosine kinase inhibitorsElectronic medical recordsResult of infectionMost patientsClinical featuresInfected patientsMedical recordsCare centerImmune effectorsPatientsViral infectionCOVID-19 in patients with CLL: improved survival outcomes and update on management strategies
Roeker LE, Eyre TA, Thompson MC, Lamanna N, Coltoff AR, Davids MS, Baker PO, Leslie L, Rogers KA, Allan JN, Cordoba R, Lopez-Garcia A, Antic D, Pagel JM, Martinez-Calle N, García-Marco JA, Hernández-Rivas JÁ, Miras F, Coombs CC, Österborg A, Hansson L, Seddon AN, López Jiménez J, Wilson MR, El-Sharkawi D, Wojenski D, Ma S, Munir T, Valenciano S, Seymour E, Barr PM, Pu J, Patten PEM, Perini GF, Huntington SF, Parry H, Sundaram S, Skarbnik A, Kamdar M, Jacobs R, Walter H, Walewska R, Broom A, Lebowitz S, Isaac KM, Portell CA, Ahn IE, Ujjani CS, Shadman M, Skånland SS, Chong EA, Mato AR. COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. Blood 2021, 138: 1768-1773. PMID: 34297826, PMCID: PMC8313815, DOI: 10.1182/blood.2021011841.Peer-Reviewed Original ResearchHistopathologic and Machine Deep Learning Criteria to Predict Lymphoma Transformation in Bone Marrow Biopsies.
Irshaid L, Bleiberg J, Weinberger E, Garritano J, Shallis RM, Patsenker J, Lindenbaum O, Kluger Y, Katz SG, Xu ML. Histopathologic and Machine Deep Learning Criteria to Predict Lymphoma Transformation in Bone Marrow Biopsies. Archives Of Pathology & Laboratory Medicine 2021, 146: 182-193. PMID: 34086849, DOI: 10.5858/arpa.2020-0510-oa.Peer-Reviewed Original ResearchMeSH KeywordsBiopsyBone MarrowDeep LearningHumansLeukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularMachine LearningReproducibility of ResultsRetrospective StudiesConceptsLarge cell transformationChronic lymphocytic leukemiaBone marrow biopsyMarrow biopsyFollicular lymphomaIndolent B-cell lymphomaLarge lymphoma cellsClinical disease progressionDiagnosis of FLFinal outcome dataB-cell lymphomaLarge tumor cellsEase of procedureAggressive chemotherapyLow morbidityLymph nodesWorse prognosisWhole slide scansHistologic findingsPatient's probabilityDisease progressionLymphocytic leukemiaLymphoma transformationClinical questionsOutcome data
2020
Clinical characteristics and mortality of patients with hematologic malignancies and COVID-19: a systematic review.
Kim J, Lee K, Kim G, Kim S, Yang J, Li H, Hong S, Ghayda R, Kronbichler A, Koyanagi A, Jacob L, Shin J, Smith L. Clinical characteristics and mortality of patients with hematologic malignancies and COVID-19: a systematic review. European Review For Medical And Pharmacological Sciences 2020, 24: 11926-11933. PMID: 33275265, DOI: 10.26355/eurrev_202011_23852.Peer-Reviewed Original ResearchConceptsHematologic malignanciesMortality of patientsLaboratory characteristicsClinical characteristicsNormal platelet countAnalyzed clinical characteristicsChronic lymphocytic leukemiaOutcomes of patientsComparison to patientsGeneral populationHematological cancer patientsHigher mortality rateMedian ageLymphocytic leukemiaPlatelet countLaboratory findingsClinical outcomesDisease courseMalignancyCancer patientsTailored treatmentPatientsCoronavirus disease 2019Mortality rateSearching PubMedCost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia
Patel KK, Isufi I, Kothari S, Davidoff AJ, Gross CP, Huntington SF. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood 2020, 136: 1946-1955. PMID: 32518952, DOI: 10.1182/blood.2020004922.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioHealth care costsFirst-line ibrutinibLifetime direct health care costsCare costsCost-effectiveness ratioParametric survival modelingUnselected older adultsDirect health care costsUS payer perspectiveCurrent pricingLife yearsFixed-duration treatmentIncremental costIncremental effectivenessPayer perspectiveHigher health care costsIbrutinib armScenario analysisMonthly costCostPricingChronic lymphocytic leukemiaMarkov modelOutcomes of COVID-19 in patients with CLL: a multicenter international experience
Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, Huntington SF, Davids MS, Brown JR, Antic D, Jacobs R, Ahn IE, Pu J, Isaac KM, Barr PM, Ujjani CS, Geyer MB, Berman E, Zelenetz AD, Malakhov N, Furman RR, Koropsak M, Bailey N, Hanson L, Perini GF, Ma S, Ryan CE, Wiestner A, Portell CA, Shadman M, Chong EA, Brander DM, Sundaram S, Seddon AN, Seymour E, Patel M, Martinez-Calle N, Munir T, Walewska R, Broom A, Walter H, El-Sharkawi D, Parry H, Wilson MR, Patten PEM, Hernández-Rivas JÁ, Miras F, Fernández Escalada N, Ghione P, Nabhan C, Lebowitz S, Bhavsar E, López-Jiménez J, Naya D, Garcia-Marco JA, Skånland SS, Cordoba R, Eyre TA. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood 2020, 136: 1134-1143. PMID: 32688395, PMCID: PMC7472711, DOI: 10.1182/blood.2020006965.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgammaglobulinaemia Tyrosine KinaseAgedAged, 80 and overAnti-Inflammatory AgentsAntiviral AgentsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 SerotherapyFemaleHumansImmunization, PassiveLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedPandemicsPneumonia, ViralProtein Kinase InhibitorsSARS-CoV-2Survival AnalysisTreatment OutcomeConceptsCOVID-19 diagnosisCLL patientsHigh riskCumulative Illness Rating Scale scoreCOVID-19Intensive care unit admissionOverall case fatality rateChronic lymphocytic leukemia patientsBruton tyrosine kinase inhibitorsMulticenter international experienceCare unit admissionSymptomatic COVID-19Severe acute respiratory syndrome coronavirus 2 infection riskCOVID-19 courseCase fatality rateRating Scale scoresFuture epidemiologic studiesLymphocytic leukemia patientsCoronavirus disease 2019Tyrosine kinase inhibitorsUnit admissionBaseline characteristicsMost patientsHospital admissionImmune dysfunctionOrbital marginal cell lymphoma and mantle cell lymphoma subclone in patient with monoclonal gammopathy of unknown significance
Hirji S, Maeng M, Tooley A, Soderquist C, Annunziata J, Kazim M. Orbital marginal cell lymphoma and mantle cell lymphoma subclone in patient with monoclonal gammopathy of unknown significance. Orbit 2020, 40: 247-251. PMID: 32363993, DOI: 10.1080/01676830.2020.1760312.Peer-Reviewed Original ResearchMeSH KeywordsAdultHumansLeukemia, Lymphocytic, Chronic, B-CellLymphoma, B-Cell, Marginal ZoneLymphoma, Mantle-CellOrbitParaproteinemiasConceptsMantle cell lymphomaCell lymphomaChronic lymphocytic leukemia/small lymphocytic lymphomaExtranodal marginal zone lymphomaMarginal cell lymphomaMarginal zone lymphomaResponse to rituximabSite of originIndolent lymphomaLymphocytic lymphomaMonoclonal gammopathyLymphomaAggressive phenotypeCell subclonesTumorSubclonesRituximabT(11;14GammopathyAuthors' knowledge,Patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply